Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
The purpose of the study is to provide expanded access (compassionate use) of 3,4 diaminopyridine to patients with Lambert-Eaton myasthenic syndrome (LEMS).
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine|
Drug: 3,4 diaminopyridine
Up to 15 patients over the age of 18 years with a diagnosis of LEMS are eligible to enroll if they are medically stable. They may receive 3,4 diaminopyridine in addition to other treatments and standard of care investigations for LEMS under supervision of the primary investigator. Safety laboratory studies and EKGs will be obtained.
The study has been approved by the University of Pittsburgh IRB. There is a local Data-Safety Monitoring Board.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00994916
|Contact: David Lacomis, MDfirstname.lastname@example.org|